Testosterone Therapy: Evidence & Safety
For men with confirmed hypogonadism, testosterone therapy improves sexual function, mood, bone density and lean mass, per Endocrine Society clinical practice guidelines. The 2023 TRAVERSE trial — over 5,000 men at elevated cardiovascular risk — found testosterone non-inferior to placebo for major adverse cardiac events, addressing the field's largest safety question. Therapy still requires proper diagnosis, conservative titration and scheduled monitoring.
Written/Reviewed by: Dr. Michael Ellis, DO — Medical Director
Scientific/Technical contribution: John Campetella
Last medical review: June 2026
What the evidence supports
Guideline-concordant therapy in men with symptomatic, biochemically confirmed hypogonadism improves libido, erectile function, mood, bone mineral density and body composition. Benefits are most consistent when baseline testosterone is genuinely low — not when normal levels are pushed supraphysiologic.
The cardiovascular safety question
For a decade, conflicting observational signals left cardiovascular safety unresolved. TRAVERSE (Lincoff 2023, NEJM) randomized 5,246 middle-aged and older men with hypogonadism and elevated CV risk to transdermal testosterone or placebo: testosterone was non-inferior for major adverse cardiac events, though atrial fibrillation, acute kidney injury and pulmonary embolism signals warrant continued monitoring.
Limitations
Testosterone is not an anti-aging drug for men with normal levels; evidence there is weak. Erythrocytosis, fertility suppression and prostate monitoring remain practical considerations. Long-term outcome data beyond ~3 years of randomized follow-up are limited.
The Integrated Wellness approach
Balance, never blast: full-axis testing (total and free testosterone, SHBG, estradiol, thyroid, metabolic context), physician-confirmed diagnosis, conservative dosing, and quarterly lab retesting with symptom and wearable-recovery tracking. Lifestyle-first when the data supports it.
A = consistent RCT/meta-analytic · B = strong observational/mixed · C = limited · Emerging = active research
- Lincoff AM, et al. (2023). Cardiovascular safety of testosterone-replacement therapy (TRAVERSE). New England Journal of Medicine.
- Bhasin S, et al. (2018). Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism.